Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.
With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry.
A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports.
India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.
A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.
The Brazilian Patent and Trademark Office has implemented several fast-track examination programmes. Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report on the effectiveness of one of them, the Green Patent Programme.
Erica Pascal of DLA Piper investigates the patentability of machine learning and its outcomes, and the complex issues that may arise.
Medical technology companies should not be left out of discussions in Europe about modernising the system for supplementary protection certificates, argues Allison Sadick of Pinsent Masons.
A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.